Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Authors:
- Elena ShklovskayaESElena Shklovskaya
- Jenny H LeeJLJenny H Lee
- Su Yin LimSLSu Yin Lim
- Ashleigh StewartASAshleigh Stewart
- Bernadette PedersenBPBernadette Pedersen
- Peter FergusonPFPeter Ferguson
- Robyn Pm SawRSRobyn Pm Saw
- John F ThompsonJTJohn F Thompson
- Brindha ShivalingamBSBrindha Shivalingam
- Matteo S CarlinoMCMatteo S Carlino
- Richard A ScolyerRichard A Scolyer
- Alexander M MenziesAMAlexander M Menzies
Open Access
Abstract
Immunotherapy targeting T-cell inhibitory receptors, namely programmed cell death-1 (PD-1) and/or cytotoxic T-lymphocyte associated protein-4 (CTLA-4), leads to durable responses in a proportion of patients with advanced metastatic melanoma. Combination immunotherapy results in higher rates of response compared to anti-PD-1 monotherapy, at the expense of higher toxicity. Currently, there are no robust molecular biomarkers for the selection of first-line immunotherapy. We used flow cytometry to profile pretreatment tumor biopsies from 36 melanoma patients treated with anti-PD-1 or combination (anti-PD-1 plus anti-CTLA-4) immunotherapy. A novel quantitative score was developed to determine the tumor cell expression of antigen-presenting MHC class I (MHC-I) molecules, and to correlate expression data with treatment response. Melanoma MHC-I expression was intact in all tumors derived from patients who demonstrated durable response to anti-PD-1 monotherapy. In contrast, melanoma MHC-I expression was low in 67% of tumors derived from patients with durable response to combination immunotherapy. Compared to MHC-I high tumors, MHC-I low tumors displayed reduced T-cell infiltration and a myeloid cell-enriched microenvironment. Our data emphasize the importance of robust MHC-I expression for anti-PD-1 monotherapy response and provide a rationale for the selection of combination immunotherapy as the first-line treatment in MHC-I low melanoma.Keywords
Funding Information
- National Health and Medical Research Council of Australia (NHMRC) (Program Grant 10930)
This publication has 30 references indexed in Scilit:
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in MelanomaJournal of Clinical Oncology, 2016
- LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK CellsCell Metabolism, 2016
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanomaJournal of Clinical Investigation, 2016
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 2016
- Tumour‐specific CD4 T cells eradicate melanoma via indirect recognition of tumour‐derived antigenImmunology & Cell Biology, 2016
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyNature Communications, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanomaJournal of Experimental Medicine, 2013
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009